What is Vertex Pharmaceuticals's deferred charges related to intra-entity transfers?

Vertex Pharmaceuticals (VRTX) reported deferred charges related to intra-entity transfers of -$15.38M in Q4 2025.

Deferred charges related to intra-entity transfers

Vertex Pharmaceuticals Deferred charges related to intra-entity transfers remained flat by 0.0% to -$15.38M in Q4 2025 compared to the prior quarter.

Analysis

StatementIncome Statement

SectionOther

CategoryRisk

SignalContext dependent

VolatilityModerate

First reportedQ1 2025

Last reportedQ4 2025Feb 13, 2026

How to read this metric

Changes often reflect internal reorganization or transfer pricing adjustments impacting the tax rate.

Detailed definition

This reflects the tax impact of deferred charges arising from the transfer of assets between entities within the same co...

Peer comparison

Common in multinational corporations with complex legal entity structures.

Metric ID: other_effective_income_tax_rate_reconciliation_deferred__57da9c

Historical Data

1 years

	FY'25
Value	-$61.50M

Deferred charges related to intra-entity transfers at Other Companies

VTR

VentasVTR View metric

DuPont de Nemours, Inc.DD View metric

CDN

CDNCDN View metric

American International GroupAIG View metric

Southern CompanySO View metric

Vulcan Materials CompanyVMC View metric

Frequently Asked Questions

What is Vertex Pharmaceuticals's deferred charges related to intra-entity transfers?: Vertex Pharmaceuticals (VRTX) reported deferred charges related to intra-entity transfers of -$15.38M in Q4 2025.
What does deferred charges related to intra-entity transfers mean?: Tax adjustments resulting from moving assets between different parts of the same company.